70 and older, any sex, with Adult Solid Neoplasm or Toxicity. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Patient Experienced Any Grade 3-5 ToxicityPrimary· 3 months
Proportion of patients who experienced grade 3-5 toxicity within 3 months of initiation of new treatment regimen. Toxicity was graded according to the National Cancer Institute (NCI) CTCAE version (v)4.0.
Group
Value
95% CI
Arm I (GA Intervention)
0.51
Arm II (Usual Care)
0.71
Patient Survival at 6 MonthsSecondary· 6 months
Proportion of patients who were alive at 6 months (183 days) after enrollment estimated by Kaplan-Meier method.
Group
Value
95% CI
Arm I (GA Intervention)
0.71
Arm II (Usual Care)
0.74
Reduced Dose IntensitySecondary· 4-6 weeks
Proportion of patients with reduced dose intensity in cycle 1.
Group
Value
95% CI
Arm I (GA Intervention)
0.49
Arm II (Usual Care)
0.35
GA-driven Recommendations Made Among Patients With Impaired Physical Performance.Secondary· Baseline
The type and frequency of GA-driven recommendations implemented for older patients with impaired physical performance and starting a new treatment regimen for advanced cancer. Physical Performance measures included: Timed Up and Go, Short Physical Performance Battery, Falls History, and OARS Physical Health.
Refer to: physical therapist (outpatient or home-based depending on eligibility for home care)
Physical Examination: decrease/eliminate blood pressure meds if blood pressure is low or low normal
Group
Value
95% CI
Arm I (GA Intervention)
67
Medication Review: minimize psychoactive meds including those used for supportive care
Group
Value
95% CI
Arm I (GA Intervention)
115
GA-driven Recommendations Made Among Patients With Impaired Functional Status.Secondary· Baseline
The type and frequency of GA-driven recommendations implemented for older patients with impaired functional status and starting a new treatment regimen for advanced cancer. Functional Status measures included: Activities of Daily Living and Instrumental Activities of Daily Living.
GA-driven Recommendations Made Among Patients With Impaired Comorbidities.Secondary· Baseline
The type and frequency of GA-driven recommendations implemented for older patients with impaired comorbidities and starting a new treatment regimen for advanced cancer. Comorbidity measure included: OARS Comorbidity.
Initiate direct communication with patient's primary care physician about the cancer treatment plan
Group
Value
95% CI
Arm I (GA Intervention)
201
Modify treatment choices: diabetes history- avoid neurotoxic agents if another option is equivalent
Group
Value
95% CI
Arm I (GA Intervention)
45
Modify treatment choices: heart failure history - minimize volume/infusion rate of agents
Group
Value
95% CI
Arm I (GA Intervention)
28
Modify treatment choices: renal impairment history - adjust as appropriate
Group
Value
95% CI
Arm I (GA Intervention)
45
Modify treatment choices: Modify dosage/schedule if concern about tolerance/worsening comorbidities
Group
Value
95% CI
Arm I (GA Intervention)
113
Provide smoking cessation counseling if the patient currently smokes
Group
Value
95% CI
Arm I (GA Intervention)
10
GA-driven Recommendations Made Among Patients With Impaired Cognition.Secondary· Baseline
The type and frequency of GA-driven recommendations implemented for older patients with impaired cognition and starting a new treatment regimen for advanced cancer. Cognition measures included: Blessed Orientation Memory Concentration and Mini Cog assessments.
Assess decision-making capacity and if lacking elicit health care proxy information and input
Group
Value
95% CI
Arm I (GA Intervention)
88
Refer to: clinician experienced in memory care
Group
Value
95% CI
Arm I (GA Intervention)
10
Refer to: social work
Group
Value
95% CI
Arm I (GA Intervention)
43
Refer to: palliative care
Group
Value
95% CI
Arm I (GA Intervention)
22
Nueropsychological testing if dementia is suspected
Group
Value
95% CI
Arm I (GA Intervention)
6
TSH if dementia is suspected
Group
Value
95% CI
Arm I (GA Intervention)
12
B12 if dementia is suspected
Group
Value
95% CI
Arm I (GA Intervention)
12
Brain imaging
Group
Value
95% CI
Arm I (GA Intervention)
16
GA-driven Recommendations Made Among Patients With Impaired Nutrition.Secondary· Baseline
The type and frequency of GA-driven recommendations implemented for older patients with impaired nutrition and starting a new treatment regimen for advanced cancer. Nutrition measures included: Body Mass Index, Weight Loss, and Mini Nutrition Assessment.
Refer to: nutritionist/clinical dietician
Group
Value
95% CI
Arm I (GA Intervention)
93
Refer to: meals-on-wheels
Group
Value
95% CI
Arm I (GA Intervention)
13
Refer to: dentist if poor dentition or denture issues
Group
Value
95% CI
Arm I (GA Intervention)
20
Refer to: speech and swallow if difficulty with swallowing
Group
Value
95% CI
Arm I (GA Intervention)
10
Inform: nutrition handout
Group
Value
95% CI
Arm I (GA Intervention)
169
Treatment modification: use caution with highly emetogenic regimens and use another if appropriate
GA-driven Recommendations Made Among Patients With Impaired Social Support.Secondary· Baseline
The type and frequency of GA-driven recommendations implemented for older patients with impaired social support and starting a new treatment regimen for advanced cancer. Social Support measure included: OARS Medical Social Support.
Confirm documented health care proxy is in medical record
Group
Value
95% CI
Arm I (GA Intervention)
78
Modify treatment choice and/or dosage
Group
Value
95% CI
Arm I (GA Intervention)
67
Refer or inform: ride assistance program
Group
Value
95% CI
Arm I (GA Intervention)
22
Refer or inform: social worker via on-site or visiting nurse services
Group
Value
95% CI
Arm I (GA Intervention)
51
Refer of inform: social worker via online services
Group
Value
95% CI
Arm I (GA Intervention)
0
Refer or inform: visiting nurse service or home health aide (if meets criteria)
Group
Value
95% CI
Arm I (GA Intervention)
17
Refer or inform: alternative living environments
Group
Value
95% CI
Arm I (GA Intervention)
0
Refer or inform: assistance programs
Group
Value
95% CI
Arm I (GA Intervention)
0
GA-driven Recommendations Made Among Patients With Impaired Polypharmacy.Secondary· Baseline
The type and frequency of GA-driven recommendations implemented for older patients with impaired polypharmacy and starting a new treatment regimen for advanced cancer. Polypharmacy measure included: medication review.
Ask patient to bring in prescribed, OTC medications, and supplements to review at the next visit
Group
Value
95% CI
Arm I (GA Intervention)
158
Contact primary care provider to help reduce regimen complexity
Group
Value
95% CI
Arm I (GA Intervention)
82
Reduce medicines solely used for hypertension or diabetes if appropriate
Group
Value
95% CI
Arm I (GA Intervention)
59
Consult the pharmacist to synchronize medication refills
Group
Value
95% CI
Arm I (GA Intervention)
52
Have pharmacist meet with the patient to evaluate drug interactions and medication counseling
Group
Value
95% CI
Arm I (GA Intervention)
59
Provide written instructions for taking new medications
Group
Value
95% CI
Arm I (GA Intervention)
184
Recommend pillbox and/or medication calendar
Group
Value
95% CI
Arm I (GA Intervention)
123
Provide handout on polypharmacy
Group
Value
95% CI
Arm I (GA Intervention)
223
GA-driven Recommendations Made Among Patients With Impaired Psychological Status.Secondary· Baseline
The type and frequency of GA-driven recommendations implemented for older patients with impaired psychological status and starting a new treatment regimen for advanced cancer. Psychological measures included: Geriatric Depression Scale and Generalized Anxiety Disorder - 7 item scale.
Provide written or verbal communication with primary care physician
Group
Value
95% CI
Arm I (GA Intervention)
44
Refer to: counseling or psychotherapy
Group
Value
95% CI
Arm I (GA Intervention)
20
Refer to: social work
Group
Value
95% CI
Arm I (GA Intervention)
42
Refer to: spiritual counseling or Chaplaincy services
Group
Value
95% CI
Arm I (GA Intervention)
18
Refer to: psychiatry if severe symptoms or if already on medications which are not adequate
Group
Value
95% CI
Arm I (GA Intervention)
11
Refer to: palliative care if other physical and/or cancer symptoms are present
Group
Value
95% CI
Arm I (GA Intervention)
24
Initiate pharmacologic therapy if appropriate in conjunction with primary care provider
Group
Value
95% CI
Arm I (GA Intervention)
18
Provide linkage to community resources
Group
Value
95% CI
Arm I (GA Intervention)
30
Sponsor's own description
This cluster randomized clinical trial compares a geriatric assessment intervention with usual care for reducing cancer treatment toxicity in older patients with cancer that has spread to other places in the body. A geriatric assessment may identify risk factors for cancer treatment toxicity and may improve outcomes for older patients with advanced cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Other trials of Comprehensive Geriatric Assessment
Trials testing the same drug.
NCT07487298 — G8 Screening Tool Validation in Older Adults With Cancer in Portugal
· not yet recruiting
NCT07302737 — Delirium and Heart Failure
· not yet recruiting
NCT06139627 — Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherap
· NA
· recruiting
NCT06022965 — Telemedicine for Improvement of Care for Older Adults With Cancer in the Underserved Community, The GAIN-S Trial
· NA
· recruiting
NCT06052826 — Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years an
· Phase 2
· recruiting
Other recruiting trials for Adult Solid Neoplasm
Currently open trials in the same condition.
NCT02432963 — Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
· Phase 1
· active not recruiting
NCT01375829 — Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
· Phase 1
· active not recruiting
NCT01281176 — High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid
· Phase 1
· active not recruiting
NCT00878163 — GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Panc
· Phase 1
· active not recruiting
NCT00045201 — Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
· Phase 1
· active not recruiting
Other Supriya Mohile trials
Trials by the same sponsor.
NCT02107443 — Improving Communication in Older Cancer Patients and Their Caregivers
· NA
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Supriya Mohile
Last refreshed: 12 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02054741.